GPs have their say on review of new diabetes drugs
In a submission to the government’s review of medicines used in the treatment of type 2 diabetes, the RACGP said the greatest burden of disease for these patients was cardiovascular death combined with microvascular complications including eye, neurological and renal disease.
It stressed that a “patient-centred” hierarchy of approaches was needed in addition to glycaemic control, including management of risks associated with hypertension and dyslipidaemia.
However, Dr Gary Deed, chair of the RACGP National Faculty of Special Interests Diabetes Network said although the introduction of novel anti-hyperglycaemic agents had attempted to address this burden of disease, there was no conclusive outcome.
“The long-term outcomes on cardiovascular risk reduction of either second-generation sulfonylurea agents, and newer agents such as gliptins and GLP1 agonists, remains as a whole, yet undetermined, at this point in time,” he